Search results for: Patricia M. Elliott

Novel devices: optimising drug delivery in multiple myeloma

9 December 2025

Share this: Download publication Henry Fong Patricia Cubi-Molla Martina Garau Key messages Novel administration devices, once considered supplementary in biologic-device combinations, may gain strategic importance as subcutaneous biologic injections become…

European Medicines Pricing and Reimbursement: Now and the Future

1 January 2007

…Pricing and reimbursement policies in Spain: current and future trends; Overview Contributors: Claude Le Pen, J-Mattias von der Schulenburg, Martina Garau, Adrian Towse, Livio Garattini, Joan Costa-i-Font, Patricia Danzon 2007…

Shaping the Research Agenda to Estimate Cost-effectiveness Thresholds for Decision Making

4 January 2016

…direction of future research in this area. The study, written by OHE’s Sarah Karlsberg Schaffer, Patricia Cubi-Molla, Nancy Devlin and Adrian Towse, and commissioned by the Association of the British…

2025 Wrapped: Health, policy shifts & what’s next

22 January 2026, 3:00pm

…Associate Principal Economist Simon Brassel Associate Director Patricia Cubi-Molla Senior Principal Economist Chris Sampson Visiting Fellow Chaired by Graham Cookson Chief Executive Watch on-demand Revisit our past webinars Insights and…

How Have HTA Agencies Evolved Their Methods Over Time?

29 April 2024

Share this: Download publication Priscila Radu Gayathri Kumar Patricia Cubi-Molla Martina Garau Eleanor Bell Jia Pan Ramiro Gilardino Julie Van Bavel Agnes Brandtmüller Katherine Nelson Melinda Goodall The many changes…

Save the Date: Drug Development in 2022, OHE’s 50th Anniversary Conference

21 June 2012

…Professor Patricia Danzon, The Wharton School, University of Pennsylvania Dr Hans-Georg Eichler, Senior Medical Officer, European Medicines Agency Dr Jens Grueger, Head, Global Health Economics and Pricing, Roche Pharmaceuticals Dr…

Around The World in HTAs: Spain – Are We There Yet?

15 March 2023

…the CIPM. Current challenges The standard process to evaluate pharmaceutical products gives a narrow time window of 10 days for REvalMed to conduct the economic evaluation of the new drug,…

Achieving Accelerated Patient Access to Cancer Care in Europe 

3 November 2025

Share this: Download publication George Bray Martina Garau Patricia Cubi-Molla Lotte Steuten Adrian Towse Key takeaways In recent years, the European Medicines Agency (EMA) has introduced a number of accelerated…

Our team

…Affairs Tim Watson Director of Marketing and Communications Amanda Cole Director Grace Hampson Director David Mott Associate Director Simon Brassel Associate Director Our economists Mikel Berdud Senior Principal Economist Patricia…